CenExel highlights industry-leading capabilities amid growing FDA momentum advancing psychedelic clinical research
Draper
•
May 27, 2026
•
0 Views
DRAPER, Utah, May 27, 2026 /PRNewswire/ -- The FDA recently announced it is shifting regulatory attention and investment for emerging psychedelic-based therapeutics treating mental health conditions. CenExel Clinical Research is answering this push with expansion to support psychedelic clinical trials…
Source: https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!
